SANOFI-ADR (SNY)

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.

SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying.

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

One of these players has split its stock in the past. The other one hasn't.

Why Sanofi Stock Flew Higher on Friday

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

Sanofi (SNY) Q3 2024 Earnings Call Transcript

SNY earnings call for the period ending September 30, 2024.

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

The company also hiked its profit outlook for the year and expects single-digit growth.

RSI Alert: Sanofi (SNY) Now Oversold

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Let's look beyond this piece of bad news from regulators.

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in...

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

/PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase...

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.